In a bid to expand its Respiratory and Monitoring Solutions
) has launched a new capnography solution, the Capnostream 20p
bedside monitor. This positive news is expected to boost investor
confidence in the stock. The company's stock returned a modest
19.9% to its investors on a year-over-year basis.
The new device, equipped with Covidien's Microstream
technology, is capable of detecting cardiopulmonary complications
at an early stage, thereby enhancing patient safety in clinical
For almost two decades, clinicians have depended on COV's
Microstream technology to effectively monitor oxygenation and
ventilation. It assists doctors to manage sedation levels and
deliver proper doses of opioids for pain management. Moreover,
the Apnea-Sat Alert algorithm feature of the Capnostream 20p
bedside monitor measures and reports recurring apnea (a temporary
condition in which a patient's breathing stops for more than 10
seconds) and oxygen de-saturation fluctuations.
According to studies, 88% of hospitalized patients may be at
risk of recurrent apneas. Yet, out of such large numbers, only
few cases are identified and treated. Management claims that the
Capnostream 20p bedside monitor increases apnea detection rate,
thereby raising standards of care. The device is compliant with
the ISO alarm standards and can be easily installed without
hampering clinical workflow.
Recently, COV launched two vessel sealing products that are
superior to their predecessors in terms of handling, control and
performance. The products are LigaSure Impact curved large jaw
open sealer/divider LF4318 and LigaSure blunt tip laparoscopic
The LigaSure Impact device promises an advanced surgical
experience with improved visibility, more intuitive jaw
positioning and enhanced ergonomics. On the other hand, the
LigaSure blunt tip laparoscopic sealer/divider ensures better
handling, and compact and ergonomic grip offering better comfort
and control for various hand sizes.
Both the products have received 510(k) clearance from U.S.
Food and Drug Administration (FDA) earlier this year. They are
designed for colorectal, general, gynecologic, urologic and
Covidien currently has a Zacks Rank #3 (Hold). While we choose
to remain on the sidelines regarding COV, medical product
companies such as
INSYS Therapeutics, Inc.
Bio-Rad Laboratories, Inc.
Boston Scientific Corp.
) are expected to do well. While INSY and BIO carry a Zacks Rank
#1 (Strong Buy), BSX has a Zacks Rank #2 (Buy).
BIO-RAD LABS -A (BIO): Free Stock Analysis
BOSTON SCIENTIF (BSX): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
INSYS THERAP (INSY): Free Stock Analysis
To read this article on Zacks.com click here.